New Safety Information Associated with the use of Zoloft™ in patients taking PimozideNEW SAFETY INFORMATION ASSOCIATED WITH THE USE OF ZOLOFT™ IN PATIENTS TAKING PIMOZIDE
| KIRKLAND, QUEBEC - March 05, 2003 |
Pfizer Canada Inc. in consultation with Health Canada has informed
Canadian health care professionals of clinically important new safety
information concerning ZOLOFT [sertraline hydrochloride] capsules, a drug
prescribed by physicians to relieve symptoms of depression, panic disorder or
obsessive-compulsive disorder.
Based on the result of a recent clinical study, the concomitant use of ZOLOFT and pimozide (an anti-psychotic medication) is now contraindicated. Patients are advised not to take ZOLOFT with pimozide as their interaction may result in arrhythmias (irregular heartbeats), which may be serious and life-threatening. Patients should be aware that the symptoms of possible arrhythmia include dizziness, palpitations and fainting, and that they should seek immediate medical attention if these symptoms occur. If you are presently being treated with this drug combination, please consult your physician before changing your current therapy. This advisory is in addition to a letter issued to health care professionals reminding them of the above-mentioned safety information. As well, the product monograph for ZOLOFT is being revised to inform physicians regarding potential adverse effects this drug combination may cause. If patients have questions regarding their current prescription, they are asked to contact their physician or pharmacist. 
-30-For more information please contact:
1-866-9Pfizer (1-866-973-4937)
These press releases were issued in Canada and are intended as reference information for Canadians. The information contained in each press release was accurate at the time of issuance, and Pfizer Canada assumes no responsibility for updating the information to reflect subsequent developments. |
| | |
For journalists/members of the media: 1 866 9Pfizer or 1 866 973-4937
Medical information: 1-800-463-6001 |
|
|
|
